<DOC>
	<DOC>NCT02010775</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).</brief_summary>
	<brief_title>Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Participants with Masseter Muscle Hypertrophy Diagnosis of Myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function Prior botulinum toxin treatment of any serotype to the masseter muscle or lower face History of dental or surgical procedure for lower facial shaping or masseter muscle reduction History of or current temporomandibular joint disorder (TMJD) or Class III malocclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>